Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 56.7%

XOMA Royalty Corporation (NASDAQ:XOMA) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 824,924 shares, a growth of 56.7% from the December 31st total of 526,343 shares. Approximately 7.2% of the company’s shares are short sold. Based on an average daily trading volume, of 869,075 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily trading volume, of 869,075 shares, the days-to-cover ratio is presently 0.9 days. Approximately 7.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several research firms have issued reports on XOMA. Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Stifel Nicolaus set a $50.00 price target on XOMA Royalty in a research note on Friday, December 12th. Zacks Research downgraded XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 18th. Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. Finally, HC Wainwright dropped their price objective on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $60.60.

XOMA Royalty Stock Performance

XOMA opened at $25.66 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. XOMA Royalty has a 52-week low of $18.35 and a 52-week high of $39.92. The firm has a market cap of $317.67 million, a P/E ratio of 34.68 and a beta of 0.89. The business’s fifty day moving average is $27.76 and its 200-day moving average is $31.16.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The firm had revenue of $9.35 million for the quarter, compared to the consensus estimate of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. Sell-side analysts expect that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Insider Activity at XOMA Royalty

In other news, CEO Owen Hughes acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average price of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the acquisition, the chief executive officer owned 102,000 shares in the company, valued at $2,555,100. This trade represents a 5,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 9.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On XOMA Royalty

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue bought a new stake in shares of XOMA Royalty in the fourth quarter worth $27,000. Russell Investments Group Ltd. lifted its holdings in XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares during the period. Tower Research Capital LLC TRC grew its position in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of XOMA Royalty during the second quarter worth about $116,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.